Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
75 hedge funds and large institutions have $340M invested in Oxford Immunotec Global PLC Ordinary Shares in 2017 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 10 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
7% more capital inflows, than outflows
Capital inflows: $32M | Capital outflows: $29.9M
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.09% less ownership
Funds ownership: 88.23% → 88.15% (-0.09%)
6% less funds holding
Funds holding: 80 → 75 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$7.4M |
| 2 |
Deerfield Management
New York
|
+$4.92M |
| 3 |
RTW Investments
New York
|
+$3.5M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$2.68M |
| 5 |
Granahan Investment Management
Waltham,
Massachusetts
|
+$2.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CV
Clarus Ventures
Cambridge,
Massachusetts
|
-$6.9M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$5.98M |
| 3 |
NLVP
New Leaf Venture Partners
New York
|
-$2.99M |
| 4 |
FI
Fosun International
Hong Kong,
China
|
-$2.56M |
| 5 |
Renaissance Technologies
New York
|
-$1.82M |
OXFD Hedge Fund Activity: Q2 2017 in Review
75 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q2 2017, worth a combined $340M — up 9.5% from $310M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of OXFD and 5 opened new positions — a net loss of 5 holders — while 29 trimmed existing stakes and 32 added.
The largest buyer was Invesco, adding an estimated $7.4M. The largest seller was Clarus Ventures, exiting entirely with an estimated $6.9M sold.
- 75 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q2 2017, down from 80 in Q1 2017.
- Funds reported $340M of Oxford Immunotec Global PLC Ordinary Shares stock for Q2 2017, up 9.5% quarter-over-quarter.
- 5 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q2 2017 and 10 closed out, a net change of -5 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q2 2017 was Invesco, an estimated $7.4M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q2 2017 was Clarus Ventures, an estimated $6.9M sold.
Based on aggregated 13F filings for Q2 2017.